By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cell Matrix Inc. (Acquired By CancerVax) 

1929 Zonal Avenue

Los Angeles  California  90033  U.S.A.
Phone: 323-343-8500 Fax: 323-343-8989

Cell Matrix Inc. (CMI) is rapidly building a leadership position in the discovery and development of inhibitors of angiogenesis. The company's lead products have been shown to be potent and highly selective inhibitors of angiogenesis, the process by which new blood vessels are formed to fuel the growth and metastasis of tumors.

CMI was founded in fall of 1999 by highly regarded scientists in the field of oncology and angiogenesis research to commercialize the recent discoveries of Peter C. Brooks, PhD as to the role of "cryptic" sites on extracellular matrix (ECM) proteins in the angiogenesis cascade. Dr. Brooks has shown that during tumor stimulated ECM remodeling, collagen denaturation exposes essential regulatory sites, which directly contribute to endothelial cell migration and new blood vessel growth.

CMI is developing monoclonal antibodies that target binding sites that are selectively exposed as a result of ECM remodeling. These antibodies have been shown to have therapeutic potential based on preclinical study results including:

  • Inhibition of new blood vessel growth
  • Inhibition of endothelial cell adhesion and migration
  • Selective staining of tumor associated blood vessels
  • Detection of elevated levels of denatured collagens in cancer patient serum
  • Inhibition of tumor growth
  • Inhibition of metastasis

CMI accomplishments in the identification of novel targets for angiogenesis regulation, discovery of molecules which block these targets, and the humanized antibody product development program have positioned CMI as a leader in drug discovery and development based on novel mechanisms of angiogenesis regulation.

Last Updated 7-10-01

Key Statistics

Ownership: Private

Web Site: Cell Matrix Inc. (Acquired By CancerVax)
Employees: 12



Eyetech Pharmaceuticals, Inc.  Opthalmic applications of antibodies to denatured collagen

Company News
Currently No News Articles